Screener
Neurocrine Biosciences NBIX Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
FAQ
- What is Neurocrine Biosciences's free cash flow?
- Neurocrine Biosciences (NBIX) reported free cash flow of $136.7M in Q1 2026.
- How has Neurocrine Biosciences's free cash flow changed year-over-year?
- Neurocrine Biosciences's free cash flow increased by 152.7% year-over-year, from $54.1M to $136.7M.
- What is the long-term trend for Neurocrine Biosciences's free cash flow?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's free cash flow has grown at a 33.2% compound annual growth rate (CAGR), from $237.8M to $748.7M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about Neurocrine Biosciences's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude